Literature DB >> 26578671

Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity".

John R Teerlink1, Fady I Malik2, David A Kass3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26578671      PMCID： PMC4654674          DOI： 10.1161/CIRCHEARTFAILURE.115.002492

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  6 in total

1.  Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Authors:  Fady I Malik; James J Hartman; Kathleen A Elias; Bradley P Morgan; Hector Rodriguez; Katjusa Brejc; Robert L Anderson; Sandra H Sueoka; Kenneth H Lee; Jeffrey T Finer; Roman Sakowicz; Ramesh Baliga; David R Cox; Marc Garard; Guillermo Godinez; Raja Kawas; Erica Kraynack; David Lenzi; Pu Ping Lu; Alexander Muci; Congrong Niu; Xiangping Qian; Daniel W Pierce; Maria Pokrovskii; Ion Suehiro; Sheila Sylvester; Todd Tochimoto; Corey Valdez; Wenyue Wang; Tatsuo Katori; David A Kass; You-Tang Shen; Stephen F Vatner; David J Morgans
Journal:  Science       Date:  2011-03-18       Impact factor: 47.728

2.  Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin.

Authors:  Yingying Liu; Howard D White; Betty Belknap; Donald A Winkelmann; Eva Forgacs
Journal:  Biochemistry       Date:  2015-03-04       Impact factor: 3.162

3.  Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Authors:  John R Teerlink; Cyril P Clarke; Khalil G Saikali; Jacqueline H Lee; Michael M Chen; Rafael D Escandon; Lyndsey Elliott; Rachel Bee; Mohammad Reza Habibzadeh; Jonathan H Goldman; Nelson B Schiller; Fady I Malik; Andrew A Wolff
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

4.  Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.

Authors:  Jens Petter Bakkehaug; Anders Benjamin Kildal; Erik Torgersen Engstad; Neoma Boardman; Torvind Næsheim; Leif Rønning; Ellen Aasum; Terje Steinar Larsen; Truls Myrmel; Ole-Jakob How
Journal:  Circ Heart Fail       Date:  2015-05-29       Impact factor: 8.790

5.  Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Authors:  You-Tang Shen; Fady I Malik; Xin Zhao; Christophe Depre; Sunil K Dhar; Patricio Abarzúa; David J Morgans; Stephen F Vatner
Journal:  Circ Heart Fail       Date:  2010-05-24       Impact factor: 8.790

6.  Separation of fluorescence signals from Ca2+ and NADH during cardioplegic arrest and cardiac ischemia.

Authors:  Monika Brachmanski; Martha Maria Gebhard; Rainer Nobiling
Journal:  Cell Calcium       Date:  2004-04       Impact factor: 6.817
  6 in total
  2 in total

1.  Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.

Authors:  Bachar El-Oumeiri; Kathleen Mc Entee; Filippo Annoni; Antoine Herpain; Frédéric Vanden Eynden; Pascal Jespers; Guido Van Nooten; Philippe van de Borne
Journal:  BMC Cardiovasc Disord       Date:  2018-05-21       Impact factor: 2.298

Review 2.  Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.

Authors:  Tariq Ahmad; P Elliott Miller; Megan McCullough; Nihar R Desai; Ralph Riello; Mitchell Psotka; Michael Böhm; Larry A Allen; John R Teerlink; Giuseppe M C Rosano; Joann Lindenfeld
Journal:  Eur J Heart Fail       Date:  2019-08-13       Impact factor: 15.534
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.